Evaluation of efficacy for immune adjuvant (lentinan(β-1,3-glucan))- containing supplementary food in patients with unresectable and recurrent gastric cancer

Biotherapy

Volumn 21, Issue 4, 2007, Pages 265-273

  Yoshino, Shigefumi ^a,b   Watanabe, Harushi ^a,c   Imano, Motohiro ^a,d   Yagi, Masao ^a,e   Suga, Tetsuya ^a,f   Nakazawa, Saburo ^a,g  

^a Medical and Food Conference for Gastroenterology

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Inoue Hospital

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Matto Ishikawa Public Hospital

^f AJINOMOTO CO INC   (Japan)

^g Yamashita Hospital

Author keywords

1,3 glucan; Gastric cancer; Lentinan; Median survival time (MST); Quality of life (QOL)

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LENTINAN; TEGAFUR;

ADJUVANT THERAPY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LENTINUS EDODES; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT CANCER; STOMACH CANCER; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 34548025382     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Japanese source
2. Chihara, G., Maeda, Y.Y., Hamuro, J., et al.: Inhibition of mouse Sarcoma 180 by the polysaccharide from Lentinus edodes (Berk) Sing. Nature (Lond.) 222: 678-679, 1969.
3. Hamuro, J., Wagner, H. and Rollinghoff, M.: β (1 → 3) glucan as a probe for T-cell specific immne adjuvant: enhanced in vitro generation of cytotoxic T-lymphocytes. Cell Immunol. 38: 328-335, 1978.
4. Suga, T., Shiio, T., Maeda, Y.Y., et al.: Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res. 44: 5132-5137, 1984.
5. Ochiai, T., Isono, K., Suzuki, T., et al.: Effect of immunotherapy with lentinan on patients' survival and immunological parameters in patients with advanced gastric cancer: results of a multi-centre randomized controlled study. Int. J. Immunother. VIII: 161-169, 1992.
6. Taguchi, T.: Clinical efficacy of lentinan on patients with stomach cancer: end point results of four-year follow-up survey. Cancer Detect. Prev. Suppl. 1: 333-349, 1987.
7. Nakano, H., Namatame, K., Nemoto, H., et al.: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology 46: 2662-2668, 1999.
8. Yoshino, S., Tabata, T., Hazama, S., et al.: Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res. 20: 4707-4712, 2000.
9. Fujimoto, K., Tomonaga, M. and Goto, S.: A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Anticancer Res. 26: 4015-4018, 2006.
10. Fragrance J. 32: 87-96, 2003.
11. Japanese source
12. Japanese source
13. Biotherapy 17: 267-273, 2003.
14. Biotherapy 20: 557-567, 2006.
15. Biotherapy 20: 568-577, 2006.
16. Biotherapy 20: 578-589, 2006.
17. Biotherapy 20: 590-606, 2006.
18. Japanese source
19. Japanese source
20. Koizumi, W., Kurihara, M., Nakano, S., et al.: Phase II study of novel oral delivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000.
21. Sakata, Y., Ohtsu, A., Horikoshi, N., et al.: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34: 1715-1720, 1998.